Sign In
Buy KYTX
$7.82
-0.0800 (-1.01%)
At Close: Jun 03, 2026
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
04:05pm, Wednesday, 21'st Aug 2024
EMERYVILLE, Calif., Aug. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients s
The Schall Law Firm Encourages Shareholders To Participate In The Investigation Of Kyverna Therapeutics Inc For Securities Law Violations
11:00am, Wednesday, 21'st Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therape
The Schall Law Firm Invites Investors To Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc
11:00am, Tuesday, 20'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therape
The Schall Law Firm Invites Investors To Join Kyverna Therapeutics Inc's Securities Fraud Investigation
11:00am, Sunday, 18'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automoti
The Schall Law Firm Encourages Shareholders To Participate In Kyverna Therapeutics Inc's Securities Fraud Investigation
11:00am, Saturday, 17'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automoti
The Schall Law Firm Invites Kyverna Therapeutics Inc's Investors To Join The KYTX Securities Fraud Investigation
11:00am, Friday, 16'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automoti
The Schall Law Firm Encourages Kyverna Therapeutics Inc's Shareholders To Join The KYTX Securities Fraud Investigation
07:45pm, Thursday, 15'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automoti
The Schall Law Firm Invites Kyverna Therapeutics Inc's Stakeholders To Participate In The KYTX Securities Fraud Investigation
10:15pm, Wednesday, 14'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automoti
Stakeholders Of Kyverna Therapeutics Inc Are Welcomed By The Schall Law Firm To Participate In The KYTX Securities Fraud Probe
07:00pm, Tuesday, 13'th Aug 2024
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX
Kyverna Therapeutics Inc's Stakeholders Are Invited By The Schall Law Firm To Join The KYTX Securities Fraud Investigation
08:00pm, Monday, 12'th Aug 2024
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
04:08pm, Monday, 12'th Aug 2024
Actively recruiting clinical trials in neurology and rheumatology with KYV-101 No severe ICANS or CRS reported in first 36 autoimmune disease patients treated with KYV-101 Received FDA RMAT Designatio
The application was evaluated based on the positive clinical outcomes in patients treated in Germany under the named-patient program The Regenerative Medicine Advanced Therapies designation allows Kyv
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotiv
The Schall Law Firm Encourages Kyverna Therapeutics Inc's Stakeholders To Join In The KYTX Securities Fraud Probe
08:00pm, Thursday, 08'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotiv
The Schall Law Firm Invites Stakeholders Of Kyverna Therapeutics Inc To Participate In The KYTX Securities Fraud Investigation
07:50pm, Wednesday, 07'th Aug 2024
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX
